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ABSTRACT
DNA ligases are important enzymes which catalyze
the joining of nicks between adjacent bases of
double-stranded DNA. NAD
1-dependent DNA ligases
(LigA) are essential in bacteria and are absent in
humans. They have therefore been identified as
novel, validated and attractive drug targets. Using
virtual screening against an in-house database of
compounds and our recently determined crystal
structure of the NAD
1 binding domain of the
Mycobacterium tuberculosis LigA, we have identified
N
1, N
n-bis-(5-deoxy-a-D-xylofuranosylated) diamines
as a novel class of inhibitors for this enzyme.
Assays involving M.tuberculosis LigA, T4 ligase
and human DNA ligase I show that these compounds
specifically inhibit LigA from M.tuberculosis. In vitro
kinetic and inhibition assays demonstrate that
the compounds compete with NAD
1 for binding and
inhibit enzyme activity with IC50 values in the mM
range. Docking studies rationalize the observed
specificities and show that among several glyco-
furanosylated diamines, bis xylofuranosylated diam-
ines with aminoalkyl and 1, 3-phenylene carbamoyl
spacers mimic the binding modes of NAD
1 with the
enzyme. Assays involving LigA-deficient bacterial
strains show that in vivo inhibition of ligase by the
compounds causes the observed antibacterial activ-
ities. They also demonstrate that the compounds
exhibit in vivo specificity for LigA over ATP-
dependent ligase. This class of inhibitors holds
out the promise of rational development of new
anti-tubercular agents.
INTRODUCTION
DNA ligases are important enzymes, vital for replication and
repair, which catalyze the joining of nicks between adjacent
bases of double-stranded DNA. These enzymes are classiﬁed
as NAD
+ or ATP-dependent based on the respective co-factor
speciﬁcities. NAD
+-dependent ligases (also called LigA)
are found exclusively in eubacteria and some viruses (1–3)
while their ATP-dependent counterparts are found in all
kingdoms of life (1). Gene knockout and other studies have
shown that NAD
+-dependent ligases are essential in several
bacteria including Escherichia coli, Staphylococcus aureus
and Bacillus subtilis (4–6). Consistent with LigA being essen-
tial, it was not possible to isolate bacteria with the gene deleted
in Mycobacterium tuberculosis (7,8). Additionally, LigA is
also not found in humans and are therefore attractive drug
targets.
Both NAD
+- and ATP-dependent DNA ligases are highly
modular proteins with distinct domain architectures. Their
mechanistic steps involve large conformational changes,
among other things (9–12), and the respective enzyme mech-
anisms are also broadly conserved. Brieﬂy, the respective
enzymes form an enzyme-adenylate intermediate in the ﬁrst
step after attacking the a-phosphorous of ATP or NAD
+.
A DNA adenylate intermediate is formed in the second step
where the bound AMP is transferred to the 50 end of DNA. The
respective enzymes then catalyze the joining of the 30 nicked
DNA to the intermediate and release AMP in the ﬁnal step.
A crystal structure of the full-length LigA with bound AMP
(Adenosine mono phosphate) is available from T.ﬁliformis
(12), while structures of the adenylation domain are avail-
able from Bacillus stearothermophilus (no co-factor) and
Enterococcus faecalis (with NAD
+) (10,11). We have recently
reported the crystal structure of the adenylation domain of
LigA from M.tuberculosis bound to AMP (13). The adenyla-
tion domain contains ﬁve out of six conserved sequence
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doi:10.1093/nar/gki1006motifs in NAD
+-dependent ligases (14) and they mainly line
the NAD
+ binding pocket (Figure 1). The active site lysine
(K123), which forms the covalent ligase-adenylate inter-
mediate, and a co-factor ‘conformation discriminating’ Glu
(E184) are part of motifs I and III, respectively (13,15).
Despite the availability of crystal structures, efforts to ﬁnd
LigA-speciﬁc inhibitors have resulted in the identiﬁcation
of only three classes of compounds, namely arylamino com-
pounds, pyridochromanones and glycosyl ureides (16,17,13).
This could partly be due to the inherent difﬁculties in ﬁnding
molecules capable of distinguishing between related binding
sites in NAD
+ and ATP ligases. Arylamino compounds and
derivatives of chloroquine inhibit the enzyme in the low mM
range but exhibit some DNA binding properties which affect
the potency but not the speciﬁcity of the tested inhibitors (16).
Pyridochromanones and glycosyl ureides, on the other hand,
are competitive inhibitors and bind to the NAD
+ binding site.
These compounds have up to nanomolar and low micromolar
afﬁnities for the enzyme, respectively. They are also able to
distinguish between the NAD
+ and ATP binding sites as sup-
ported by both inhibition assays and docking studies (17,13).
M.tuberculosis, the etiological agent of the disease, kills
more than 2 million people every year worldwide in concur-
rence with HIV-related infections (18). Moreover, appearance
of multi drug resistant (MDR) strains of M.tuberculosis to
many, if not all, of the existing drugs has been noted. This
has necessitated more urgent and new approaches to ﬁnd novel
therapies based on different mechanisms of action (19).
As part of a long range goal we are using virtual screening
strategies to identify novel classes of inhibitory molecules
which bind competitively to the co-factor binding site and
to develop them as potential anti-tubercular entities. We had
earlieridentiﬁed glycosyl ureides as potent, competitive LigA-
speciﬁc inhibitors (13). Here, we report a series of 5-deoxy-
xylofuranosylated amines active against the M.tuberculosis
NAD
+-dependent DNA ligase with IC50 values in the mM
range and able to discriminate between the human (ATP-
dependent) and pathogen enzymes. This class of compounds
had earlier been reported by us as having anti-tubercular
activity (20). In vitro inhibition assays show speciﬁcity of
thecompoundsforMtuLigAoverATP-dependentligasesfrom
human and bacteriophage sources and also that they compete
with NAD
+ for binding. In vivo inhibition/antibacterial
assays involving LigA-deﬁcient bacterial strains rescued
with MtuLigA suggests that inhibition of MtuLigA is the
cause of the earlier reported anti-tubercular activity of the
compounds. These results pave the way for rational optim-
ization and synthesis of second generation inhibitors with
potent anti-tubercular activity.
MATERIALS AND METHODS
Virtual screening protocol
Docking calculations were carried out using AUTODOCK
v3.0.5 (21). A PERL/PerlTk/Python-based script was used
to add the capability of automated docking against a ligand
database to AUTODOCK. A computer cluster consisting of
SGI ORIGIN350 servers and SGI OCTANES were used for
the computation and analysis of docked complexes. Two mod-
els each of well-characterized NAD
+- and ATP-dependent
DNA ligases were selected as targets for in silico screening
calculations.
Preparation of templates. MtuLigANAD. The crystal structure
of MtuLigA (PDB: 1ZAU)was used as the basis forgenerating
the NAD
+ binding site by superposing the individual sub-
domains in the structure onto the E.faecalis LigA-NAD
+
co-crystal structure (PDB: 1TAE).
E.faecalis ligase. The NAD
+-dependent ligase from
E.faecalis (PDB: 1TAE) in which the NAD
+ binding pocket
is well deﬁned was also chosen.
ATP-dependent DNA ligases. To compare docking results
and to identify compounds with speciﬁcity for LigA, well-
characterized ATP ligases from two different sources, viral
(T4) and human ATP-dependent ligase I (PDB: 1X9N) were
also chosen for docking studies. Selection of human ligase
was based on the fact that M.tuberculosis is a major human
pathogen. A homology model for T4Lig was generated using
MODELLER6v2 (22) where T7DNA ligase (23) (PDB: 1A0I)
was the template. The model was reﬁned by subjecting it to a
few rounds of minimization using the DISCOVER_3 module
in InsightII (24). The stereo-chemical quality of the model was
veriﬁed using PROCHECK (25) and WHAT IF (26). Prior to
docking studies,crystallographic waters and heteroatoms were
removed from the crystal structures. Polar hydrogens were
added and also Kollman charges were assigned to all atoms
(http://www.scripps.edu/mb/olson/dock/autodock/tools.html).
Ligand preparation. An in-house database consisting of over
15000 compounds was used. This database can be ﬁltered
for speciﬁc properties, such as anti-tubercular activity, etc.
based on prior experiments and synthesis expertise is also
available. The 3D structures of the ligands were built
and optimized using the BUILDER module in InsightII.
The ligand’s translation, rotation and internal torsions were
assigned for AUTODOCK runs.
Figure 1. Co-factor binding site in NAD
+-dependent DNA ligase from
M.tuberculosis. Parts from sub-domains 1a and 1b which make up the binding
site are depicted in lavender and cyan, respectively. Interacting residues with
NAD
+ are indicated in blue and labeled for clarity, while the co-factor itself is
showninred.BoundAMPfromthecrystalstructure(PDB:1ZAU)isindicated
in yellow. This and the next figure was made using PyMOL (41) (http://www.
pymol.org).
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was centered on Lys123 for 1ZAU, Lys159 for T4, Lys120
for 1TAE and Lys568 for 1X9N in the docking studies.
An 80 · 80 · 80 3D afﬁnity grid with 0.375 s spacing was
calculated, respectively, for each of the following atom
types C, A (aromatic C), N, O, S, H, F, Cl, Br and e by
Autogrid 3.0.
The Lamarckian genetic algorithm implemented in
AUTODOCK v3.0.5 was used. Docking parameters were as
follows: 100 docking trials, population size of 150, random
starting position and conformation translation step ranges
of 1.5 s, rotation step ranges 35, elitism of 1, mutation rate
of 0.02, cross-over rate of 0.8, local search rate of 0.06
and 10 million energy evaluations. The jobs were distributed
to the computer cluster. The docked conformations were clus-
tered by the use of a tolerance of 1.5 s root-mean-square
deviation. The complexes were sorted based on the scoring
function and ﬁtness scores implemented in the program. Con-
trol docking experiments were carried out to reproduce the
AMP/NAD
+ complexes in the crystal structures. Selected
compounds from the best 10% docked complexes (as observed
from the AUTODOCK scoring function) were taken up further
for in vitro and in vivo ligase assays.
Synthesis of compounds 1–5
5-Deoxy-xylofuranosylated diamines 1 and 2 were synthes-
ized by conjugate addition of 1 mole equivalent of diamines
with glycosyl oleﬁnic ester I followed by reduction of the
intermediate glycosyl amino esters II and III by the protocol
already reported by us (20,27) and compounds were isolated
as diastereochemically pure by column chromatography
(Scheme 1). Compound 3 was prepared by reductive amino-
alkylation of xylofuranose dialdose with 1, 12-dodecyl amine
as already reported by us (27). Compound 4 was prepared
by reaction of xylofuranosylated amino ester IV (28) with
1, 3-phenylene diisocyanate followed by reduction of the
intermediate amino ester V with LiAlH4. However, synthesis
of compound 5 was achieved simply by reacting glycosyl
amino ester IV with 1, 4-phenylene diisocyanate following
our earlier protocol (29,30) (Scheme 2).
In vitro assay
In vitro assays for ligase activity were performed using
a double-stranded 40 bp DNA substrate carrying a single-
strand nick between bases 22 and 23 as reported earlier (13).
Brieﬂy, the substrate was created in TE buffer by annealing 22
and 18mer DNA complementary strands to a 40mer (50-ATG
TCC AGT GAT CCA GCT AAG GTA CGA GTC TAT GTC
CAG G-30). At the 50 end, the 18mer was radiolabeled with
[g-
32P]ATP (3000 Ci/mmol, Board of Radiation and Isotope
Technology, Mumbai). This labeled, nicked 40 bp DNA sub-
strate was used to assay the in vitro inhibitory activity of
different compounds against MtuLigA, T4Lig and HuLigI.
Amounts of the respective enzymes were optimized for similar
ligation extents in the absence of any inhibitor under assay
conditions.
Full-length MtuLigA was cloned, expressed and puriﬁed as
reported earlier (13). The assays were carried out using 2 ng
of the puriﬁed protein. Reaction mixtures (15 ml) containing
50 mM, Tris–HCl, pH 8.0, 5 mM DTT, 10 mM MgCl2,
10% dimethyl sulfoxide (Me2SO), 50 mM NAD
+, 2 pmol of
32P-labeled nicked duplex DNA substrate and different con-
centration of compounds were incubated for 1 h at 25 C.
Subsequently, they were quenched with formamide and
EDTA. The products were resolved electrophoretically on a
15% polyacrylamide gel containing 8 M urea in TBE (90 mM
Tris-borate and 2.5 mM EDTA). Autoradiograms were
developed and ligation extents were measured using Image
Master 1D Elite software (Amersham). All compounds were
dissolved in 100% Me2SO. The compound solutions com-
prised one-tenth volume of the ligation reaction mixture;
thus, 10% Me2SO was included in all the control reactions.
The same procedure was followed for T4 DNA ligase also.
Brieﬂy, T4 DNA ligase assay was carried out in a volume of
15 ml containing 0.05 U of enzyme (Amersham), 2 pmol of
labeled template and 66 mM ATP in 66 mM Tris–HCl, pH 7.6,
6.6 mM MgCl2, and 10 mM DTT and 10% Me2SO. The
Human DNA ligase I expression plasmid was transformed
into E.coli BL21 (DE3) and puriﬁed as described previously
(31). Puriﬁed protein was concentrated to 2 mg/ml. An aliquot
of 2mg protein was used for assay in 50 mM Tris–HCl, pH 8.0,
10 mM MgCl2, 5 mM DTT, 50 mg/ml BSA and 1 mM ATP as
described above.
Calculation of IC50 values. The IC50 values were determined
by plotting the relative ligation activity versus inhibitor
concentration and ﬁtting to the equation:
Vi=V0¼IC50=ðIC50 þ½ I Þ
using GraphPad Prism . V0 and Vi represent rates of ligation
in the absence and presence of inhibitor, respectively, and [I]
refers to the inhibitor concentration.
Scheme 1. Synthesis of glycosyl amines with aminoalkyl spacers.
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Fluorescence assay. DNA intercalating properties of the com-
pounds, if any, were measured by attempting to displace
ethidium bromide from DNA. Detection of its displacement
from DNA is based on the strong loss in ﬂuorescence that
should occur upon its detachment from DNA (32). The assay
mixture contained 5 mg of calf thymus DNA, 5 mM ethidium
bromide, 25 mM Tris–HCl, pH 8.0, 50 mM NaCl and 1 mM
EDTA in a total volume of 100 ml.
Change in ethidium bromide ﬂuorescence was followed on
addition of increasing inhibitor concentrations at excitation
and emission wavelengths of 485 and 612 nm, respectively.
Gel shift assay. An aliquot of 100 ng of plasmid DNA
(pUC 18) was incubated with increasing compound concen-
tration in TE at 25 C for 1 h. Subsequently, the DNA was
analyzed in a 1% agarose gel.
Mode of inhibition
Using Michaelis–Menten kinetics, saturating substrate con-
centration for MtuLigA was determined by increasing the
NAD
+ concentration from 0.2 to 50 mM. Km for NAD
+ was
determined in10%Me2SOusingthe assayprocedure. Kinetics
for different amount of compounds were determined using
varying concentrations of NAD
+ from 0 up to 50 mM under
standard assay conditions as described earlier.
Rate of the ligation reaction was determined based on the
extents of ligation by scanning the gel using ImageMaster
1D Elite software (Amersham). Data were plotted using
Michaelis–Menten kinetics in Graph Pad Prism . Similarly,
Ki values were determined by plotting the apparent Km values
against the respective compound concentrations. Mode of
inhibition was determined through standard analysis of
Lineweaver–Burk kinetics.
Antibacterial activity
The recombinant plasmid pRBL (33) containing the gene for
T4Lig in pTrc99A was transformed into E.coli GR501 ligA
ts
mutant (34). In order to have the same genetic background, the
MtuLigA clone in pTrc99A (13) was also transformed into
E.coli GR501. In growth experiments the strains expressing
MtuLigA or T4Lig were compared with a control GR501
strain carrying empty pTrc99A without any gene insertions
at 37 C. As reported earlier (17) and reproduced by us, the
temperature-sensitive E.coli GR501 ligA
ts strain grows well at
30 C while it is strongly delayed at 37 C. Complementation
with either MtuLigA or T4Lig restores the growth of the
mutant strain.
Minimum inhibitory concentration (MIC) values for the
inhibitors were determined for MtuLigA and T4Lig in E.coli
GR501 ligA
ts mutant along with Salmonella typhimurium LT2
and its DNA ligase minus (null) mutant derivative which had
been rescued with a plasmid (pBR313/598/8/1b) encoding the
T4Liggene (35) inordertocheck thespeciﬁcityofcompounds
for NAD
+-dependent ligases from other sources as well. Anti-
microbial activity was monitored in microtiter plates using
microdilution assay technique in a volume of 200 ml.
Approximately 10
5 CFU/ml in the case of E.coli LigA
ts
mutant, 10
6 CFU/ml in the case of S.typhimurium LT2 and
its mutant LigA
  strain, rescued with T4Lig, were incubated
with different compound concentrations under ambient con-
ditions for 20 h and MIC were determined on the basis of the
presence of any visible growth.E.colimutant strainwas grown
in Luria–Bertani (LB) medium while nutrient broth was used
for S.typhimurium strains. The media contained 20 mg/ml
polymyxinB nonapeptide to facilitate passage of the inhibitors
across the outer membrane.
Table 1. In silico screening using AUTODOCK v3.0.5
Compounds MtuLigANAD EfaLigA T4Lig HuLigI
NAD  14.7  14.9 — —
AMP  10.7  11.9  9.3  10.8
Chloroquine  10.7  10.8  9.3  10.6
Doxorubicin  18.6  19.7  13.7  17.0
Pyridochromanone 3  16.7  17.7  13.5  17.7
1  15.8  16.9  12.4  12.6
2  11.2  12.2  11.7  11.0
3  13.8  11.8  10.7  12.0
4  14.3  15.2  13.0  14.9
5  11.2  12.1  13.3  14.4
The docking energies are in kcal/mol. MtuLigANAD, EfaLigA, T4Lig and
HuLigI refer to the respective ligases from M.tuberculosis, E.faecalis,T 4
bacteriophage and human sources mentioned in the text.
Scheme 2. Synthesis of glycosyl amines with phenylene carbamoyl spacers.
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+-dependent DNA ligase, T4 DNA ligase and human DNA ligase I by the respective compounds
S. no. Compounds IC50 (mM)
MtuLigA T4Lig HuLig I
1 46.2 ± 1.6 455 ± 9.0 320 ± 10.0
2 260 ± 4.0 40.0 ± 3.6 72 ± 3.4
3 11.4 ± 1.2 8.0 ± 0.8 27.0 ± 1.2
4 85.0 ± 1.3 462 ± 10.0 380 ± 7.4
5 225 ± 6.2 55.0 ± 2.0 94.0 ± 3.2
6 5.0 ± 0.3 3.0 ± 0.2 ND
a
7 46.0 ± 2.5 1600 ± 15.0 ND
aND refers to ‘not determined’.
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Virtual screening
Choice of models and NAD
+ binding site. Available crystal
structuresofNAD
+-dependentDNAligasesinclude thosewith
NAD
+ (PDB: 1TAE) (11) and AMP (PDB: 1ZAU) (13). The
AMP binding site consists only of residues in subdomain 1b.
On the other hand, the NAD
+ binding site is generated when
the mobile subdomain 1a comes into close proximity of
subdomain 1b (Figure 1). Mutational analysis of corres-
ponding conserved residues in this class of enzymes has
shown, among other things, that the tyrosine corresponding
to Y31 of MtuLigA is essential for activity while mutating
those corresponding to F44 diminishes activity (36). This is
in addition to other residues in subdomain 1b, such as
K123 and E184, which were earlier identiﬁed as essential
for activity (37). The use of the complete NAD
+ binding
site, as opposed to only subdomain 1b which binds AMP,
in virtual screening experiments would be expected to pick
up molecules that compete with NAD
+. We therefore gener-
ated the NAD
+ binding site in MtuLigA based on the MtuLigA
and EfaLigA crystal structures as reported earlier (13,11)
(Figure 1) and used it for virtual screening. We were also
interested in compounds that could potentially distinguish
between NAD
+ and ATP binding sites in the respective
enzymes as compounds having less afﬁnity for the ATP bind-
ing site would be more interesting as expectedly they were
likely to have less afﬁnity for the major human DNA Ligase I
enzyme. To improve the chances of identifying potential
inhibitors with such distinguishing properties, four models
(Table 1) were used for virtual screening experiments. Two
structures each, namely EfaLigA (PDB: 1TAE) and MtuLigA
(PDB: 1ZAU), were used in screening for afﬁnity for
NAD
+-dependent enzymes while T4 DNA ligase (a homology
model) and Human DNA ligase I (PDB: 1X9N) were used
for ATP-dependent enzymes.
Database used and in silico screening. The top 10% of the
docked complexes were sorted based on the scoring function
and ﬁtness scores as implemented in the AUTODOCK v3.0.5
program. Control docking experiments were able to reproduce
the AMP/NAD
+ complexes in their crystal structures with
respective enzymes (13) and were used to optimize the dock-
ing parameters. The docking energy of chloroquine was much
less than NAD
+ in line with earlier reports (16) that chloro-
quine does not interact with the co-factor binding site in LigA
(Table 1). The other selected compounds had comparable
predicted binding afﬁnities to NAD
+. We then focused our
efforts on the glycosylamines for further analysis as earlier
reports had suggested that certain compounds exhibited
anti-tubercular activity (20) although their mode of action
is unknown. The selected glycofuranosylated diamines could
be divided further into two subclasses (Table 2), namely
bis xylofuranosylated diamines with aminoalkyl spacers
(compounds 1, 2 and 3) and those with phenylene
carbamoyl-based spacers (compounds 4 and 5, respectively).
An analysis of the AUTODOCK predicted docking modes
of the compounds suggests that they interact with several
essential residues in the NAD
+ binding site (Figure 2).
Among compounds with aminoalkyl spacers (1, 2 and 3),
1 and 3 have electrostatic interactions with K123 and E184.
They also interact with essential residues, such as Y31 and
D45, from subdomain 1a which binds to the NMN moiety of
NAD
+ (Figure 2A). Compound 2, however, exhibits polar
AB
Figure2. (A)Interactionsofcompounds1,2and3(thosewithaminoalkylspacers)intheNAD
+bindingsiteoftheenzymefromM.tuberculosis.Thecompoundsare
shown in green, red and pink respectively while the NAD
+ binding region is depicted as a light green wire mesh. Key interacting residues are shown as blue sticks
and labeled for clarity. (B) Interactions of compounds 4 and 5 (those with phenylene carbamoyl spacers) in the NAD
+ binding site of the M.tuberculosis enzyme.
The compounds are depicted in green and red, respectively. The color scheme is similar to (A).
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+ binding
site although it has van der Waals contacts with E184 also.
These are in addition to other interactions with conserved
residues not directly interacting with bound NAD
+.
Among the compounds with phenylene carbamoyl spacers,
namely compounds 4 and 5, respectively, the former interacts
more extensively with residues directly and indirectly
involved in NAD
+ recognition. The interactions include
those with the essential E184 and D45. Compound 5 on the
other hand has less extensive interactions with residues in the
NAD
+ binding site, although it also interacts with E184 and
D45 (Figure 2B). These compounds were then synthesized and
assayed as described.
Synthesis
The identiﬁed compounds were synthesized as per our earlier
reported protocols (20,27–30). Schematic representations of
the synthesis of glycosylamines with aminoalkyl and pheny-
lene carbamoylspacersareshown inSchemes1and2,respect-
ively. The purity and integrity of the compounds were veriﬁed
according to the standard procedures (data not shown).
In vitro DNA ligase inhibition assays
We assayed for the in vitro inhibitory potency of the com-
pounds against the full-length NAD
+-dependent enzyme from
M.tuberculosis, the major human DNA ligase I and bacterio-
phage T4 DNA ligase, respectively. The latter two, as men-
tioned before, are ATP-dependent enzymes and we were
interested in compounds which could potentially distinguish
between NAD
+- and ATP-dependent ligases. Chloroquine and
doxorubicin (compounds 6 and 7, Table 2) were also used as
control inhibitors as reported by us earlier (13). The results are
summarized in Table 2.
Of the three bis xylofuranosylated diamines with 3, 10 and
12 carbon spacers, respectively, compound 1 with 3-carbon
A
B
Figure 3. Competitive inhibition of MtuLigA with respect to NAD
+ by the bis
xylofuranosylated diaminewith threecarbon spacer (Compound1) andwith 1,
3-phenylene carbamoyl spacer (Compound 4). Data were fitted using
standard linear regression. The double-reciprocal plots clearly indicate
competitive binding between NAD
+ and compounds 1 and 4.( A) Activity
of MtuLigA measured in the presence of rising concentrations of compound
1 (0–250 mM) and NAD
+ (0–50 mM). (B) Activity of MtuLigA measured in
the presence of rising concentrations of compound 4 (0–450 mM) and NAD
+
(0–50 mM).
A
B
Figure 4. Linear regression plots of the inhibitor concentrations versus the
Kmapp. The Ki values are marked with an arrow. The plots correspond to
(A) compound 1 and (B) compound 4, respectively.
7096 Nucleic Acids Research, 2005, Vol. 33, No. 22spacer was able to distinguish between the two classes of
enzymes by up to 9-fold and exhibited speciﬁcity for the
M.tuberculosis enzyme. Compound 3 could also distinguish
between the human and M.tuberculosis enzymes by a factor of
2 and has higher afﬁnity for the latter with IC50 values in the
low micromolar range. Compound 2, on the other hand, bound
to the ATP-dependent enzymes from human and bacterio-
phage sources with higher afﬁnities.
Of the two compounds 4 and 5 with phenylene carbamoyl-
based spacers, compound 4 with the 1,3-linker could distin-
guish between the human and tuberculosis enzymes exquis-
itely and exhibited a higher afﬁnity for the latter. Compound 5
with the 1,4-linker had higher afﬁnity for the ATP-dependent
enzymes in the assays.
In silico docking analysis suggested an overlap of the
binding sites of NAD
+ and glycosylamines. We therefore
chose compounds 1 and 4 to evaluate by standard kinetics
if the compounds act competitively with NAD
+ in the overall
nick sealing reaction in vitro. In the absence of the inhibitor
we determined a Km of 1.56 mM for NAD
+ in the presence of
10% Me2SO in the assay mixture, which agrees well with
previously reported data (8,13). In our inhibition studies,
when the amount of NAD
+ was increased up to 50 mM in the
presence of rising concentrations of compound 1 (0–250 mM)
and compound 4 (0–450 mM) under saturating DNA concen-
tration (0.85 mM), the kinetics clearly indicated competitive
inhibition of NAD
+ by the compounds as also visualized
in double-reciprocal plots (Figure 3). The linear regression
using the apparent Km values leads to a Ki of 72.8 mM for
compound 1 and 98.3 mM for compound 4 (Figure 4).
These results strongly suggest that the binding sites of the
glycosylamines and NAD
+ overlap with each other.
The in vitro inhibition assay results correlate well with the
docking results and are rationalized in ‘Discussion’.
DNA binding assay
We carried out ethidium bromide displacement assays for the
selected inhibitors in the current study to probe for interactions
with DNA, if any. It was reported earlier that aryl amino
compounds, a class of DNA ligase inhibitors, generally
intercalate with DNA and this might inﬂuence their inhibit-
ory potencies (16). Compounds were added to a maximum
concentration of 250 mM which represents a 50-fold excess
over ethidium bromide. We could not ﬁnd any evidence for
general interaction of the compounds with DNA by examining
the ﬂuorescence(Figure 5).Wealsocarried outgel shiftassays
where the electrophoretic mobility of DNA was checked in
the presence of increasing inhibitor concentrations. These
experiments also did not support any general interaction of
glycosylamines with DNA. Subsequently, the compounds
were assayed to examine whether they inhibit the action of
A
B
Figure 5. Ethidium bromide displacement assay. Relative fluorescence
intensity measured in the presence of 10 (dark dotted lines) and 50 times
(continuous lines) increasing concentrations. The control (light dotted lines)
is in the absence of the respective inhibitors. (A) and (B) correspond to
compounds 1 and 4, respectively.
Table 3. Antibacterial activity of glycosylamines
Compounds MIC (mg/ml)
E.coli GR
501+ pTrc99A
E.coli GR
501+ Mtu NAD
+ ligase
E.coli GR
501+ T4 DNA ligase
S.typhimurium
LT2
S.typhimurium
TT15151
1 0.2 12 54 10.5 52
4 0.1 18 76 20 80
TheMICvaluesweredeterminedbybrothmicrodilutionforthebacterialstrainsE.coliGR501andS.typhimuriumLT2(whichcontainsitsNAD
+ligase)andtheDNA
ligase-minus(null)derivativeTT15151(lig-2::MudJ/pBR313/598/8/1b[T4Lig
+]AMPr)(35)rescuedwithT4Lig
+plasmid.E.coliGR501ligA
tsisastraincontaining
atemperature-sensitiveligasemutant(34);adefectthatisrestoredbytheoverexpressionofMtuLigA(13,38)orT4Lig(34).PolymyxinBnonapeptide(20mg/ml)was
added to the growth medium to facilitate passage of the inhibitors across the outer membrane of the cell.
Nucleic Acids Research, 2005, Vol. 33, No. 22 7097the enzyme inbacteria also and whetherthat would be inimical
to their growth.
Antibacterial/in vivo assays
We used two bacterial systems to evaluate the in vivo inhibi-
tion of NAD
+ ligases. In the ﬁrst instance we chose the E.coli
GR501 strain which harbors a temperature-sensitive lig251
mutation in its LigA. Its growth is strongly impaired at physio-
logical temperatures while at 30 C it grows well.Thisdefect is
overcome when it is rescued by NAD
+ or ATP-dependent
ligases (17,34,38). This strain has been used therefore to
demonstrate the in vivo speciﬁcity of inhibitors for LigA.
We accordingly used pTrc99A-based systems involving
MtuLigA and T4Lig (33) in this strain and also reproduced
earlier results (34,38).
Asasecondsystemwe useda strainofthe prominent human
pathogen S.typhimurium LT2 (39) where again NAD
+ ligase
has been shown to be essential. We also used its DNA ligase
null derivative TT15151 (35) that had been rescued with T4
DNA ligase. These two systems give a handle on not only
whetherthecompounds inhibitLigAinvivobutalsoallowsfor
probing differences in efﬁcacy against ATP-dependent ligases
in similar bacterial systems.
Results of these assays are tabulated in Table 3 and results
of the growth inhibition studies involving the S.typhimurium
strains are shown in Figures 6 and 7. There is a low residual
ligase activity in the mutant E.coli GR501 strain as compared
with the corresponding growth rescued versions (growth
curves not shown) because the latter possesses a high
amount of expressed ligase. This leads to the much higher
sensitivity of the mutant strain for the compounds (Table 3).
The in vivo results are consistent with the in vitro inhibition
assays. For both the tested compounds, namely 1 and 4, the
MICs are less for the strain rescued by MtuLigA and higher for
the T4 DNA ligase rescued version. The same trend is
observed in the S.typhimurium system also where the com-
pounds exhibit higher sensitivity for the wild-type salmonella
strain (harboring its natural NAD
+-dependent DNA ligase)
as compared with its ligase-deﬁcient variant rescued by
T4Lig.
Correspondingly, growth inhibition studies performed using
the compounds are in line with the above results. Increasing
the inhibitor concentration leads to more bactericidal activity
against the S.typhimurium LT2 strain compared with its ligase
null derivative (rescued by T4Lig) (Figure 6A and B and
Figure 7A and B) at the same compound concentration.
Cell viability which was tested using the compounds again
show thatthewild-typeS.typhimurium LT2strainislessviable
at same compound concentrations compared with the viability
of the ligase-deﬁcient variant rescued with T4Lig (Figures 6C
and 7C).
The in vivo assay results demonstrate that compounds 1 and
4 have higher speciﬁcity for NAD
+-dependent ligases and
strongly suggest that the observed antibacterial activities
are due to in vivo inhibition of LigA.
DISCUSSION
One of the main differences in the sequences of NAD
+- and
ATP-dependent ligases in the co-factor binding domain is that
A
B
C
Figure 6. Bactericidalactivityofcompound 1.Effecton growthasreflectedin
changes of the optical density at 600 nm of (A) S.typhimurium LT2 and (B) its
DNAligaseminus(null)derivativeTT15151[Lig
 /T4Lig
+]ontheirrespective
exposures to compound 1 at 5.25–26.25 mg/ml representing 0.5–2.5 times the
MIC value. The arrow indicates the point at which the compound was added.
(C) Comparative viability between S.typhimurium LT2 (top row) and its
corresponding DNA ligase minus (null) derivative TT15151[Lig
 /T4 Lig
+]
(bottom row) rescued with a plasmid containing the gene for T4 Ligase as
shown by surviving CFU, 5 h after addition of compound 1 to the growth
medium. The cells were plated at dilution ratios of 10
 4 on nutrient agar
and the indicated MIC values correspond to that of S.typhimurium LT2 against
the inhibitor. The control (marked ‘C’) and the amount of added inhibitor as
multiples of MIC are also indicated.
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+ binding site are conserved
across species while they are not in ATP-dependent ligases.
Subdomain 1a occurs only in LigA and is absent in
ATP-dependent ligases. Such differences can be potentially
exploited in designing LigA-speciﬁc inhibitors. It is instruc-
tive in this context to examine the docking modes of the
inhibitors and compare them with the in vitro inhibition
assay results against NAD
+- and ATP-dependent ligases.
Among the compounds 1, 2 and 3 (those with aminoalkyl
spacers, Table 2), compound 2 has higher afﬁnity for human
DNA ligase I. On the other hand, compounds 1 and 3 can
distinguish between MtuLigA and the human enzyme and are
more speciﬁc for the former. These results correlate well with
the observed docking modes of compounds 1 and 3, respect-
ively (Figure 2A).Both compounds seem to mimic the binding
modes of NAD
+ and have more interactions within the bind-
ing site of the co-factor. This seems to be the basis for their
ability to distinguish between MtuLigA and the human
enzyme. Compound 2, on the other hand, has more interac-
tions outside of the NAD
+ binding site. This supposedly
decreases its speciﬁcity for the NAD
+-dependent ligase.
The same analogy extends to the cases of compounds 4
and 5 (those with phenylene carbamoyl spacers). Compound
4 which exhibits higher speciﬁcity for the M.tuberculosis
enzyme (Figure 2B and Table 2) has more extensive contacts
within the NAD
+ binding site compared with compound 5.
The latter compound has more interactions outside the
NAD
+ binding site. The in vitro assays are in agreement and
show that compound 5 has less afﬁnity for MtuLigA. The
present results may therefore be used as a guiding rule in
selecting inhibitors with the ability to distinguish between
NAD
+- and ATP-dependent DNA ligases.
The compounds described here are able to discriminate
between the two classes of DNA ligases. The in vivo results
are in good consonance with the in vitro assay results and
demonstrate that the inhibitors have higher afﬁnity for
NAD
+-dependent ligases in vivo also. We used two different
LigA-deﬁcient strains for the in vivo assays. While the E.coli-
based strain was rescued with LigA from M.tuberculosis,
the other strain was a S.typhimurium one containing its own
LigA. The efﬁcacy of compounds 1 and 4 against both strains
point to their potential development as broad antibacterials
also. This is also the case with pyridochromanones, another
class of LigA-speciﬁc inhibitors, which have also been found
to inhibit LigA from at least E.coli and M.tuberculosis (17,8).
The similar binding site architecture in NAD
+- and ATP-
dependent ligases makes it difﬁcult to identify inhibitors
capable of distinguishing between them. However, this is
an important and necessary step for exploiting the enzyme’s
potential as a drug target. Several sequence motifs lining the
co-factor binding site are conserved across bacteria (40),
and it is therefore naturally expected that inhibitors of LigA
A
B
C
Figure 7. Bactericidal activity of compound 4. Effect on growth as reflected
in changes of the optical density at 600 nm of (A) S.typhimurium LT2 and (B)
its corresponding DNA ligase minus (null) derivative TT15151[Lig
 /T4 Lig
+]
on their respective exposures to compound 4 at 10–50 mg/ml representing
0.5–2.5 times the MIC value. The arrow indicates the point at which the
compound was added. (C) Comparative viability between S.typhimurium
LT2 (top row) and its corresponding DNA ligase minus (null) derivative
TT15151[Lig
 /T4 Lig
+](bottom row) rescued with a plasmid containing the
geneforT4LigaseasshownbysurvivingCFU,5hafteradditionofcompound
4 to the growth medium. The cells were plated at dilution ratios of 10
 4 on
nutrientagarandtheindicatedMICvaluescorrespondtothatofS.typhimurium
LT2 against the inhibitor. The control (marked ‘C’) and the amount of added
inhibitor as multiples of MIC are also indicated.
Nucleic Acids Research, 2005, Vol. 33, No. 22 7099will act as general antibacterials also. A further challenge,
however, is to tweak the speciﬁcity such that the inhibitors
are more potent against speciﬁc pathogens, such as
M.tuberculosis. In the present work, we have identiﬁed
glycofuranosylated diamine-based inhibitors which are more
speciﬁc for LigA and which were known from earlier work
to possess some anti-tubercular activity [(20); our unpublished
data]. The in vitro assays against MtuLigA and in vivo experi-
ments with the LigA-deﬁcient strains reported here suggest
that inhibition of MtuLigA is the basis of the observed anti-
tubercular activity of the compounds although an alternate
mechanism in the pathogen cannot be ruled out. These com-
pounds also do not appear to exhibit any unwanted general
interactions with DNA. Indeed, ongoing experiments for the
next generation of more potent anti-tubercular compounds
include structural studies on the enzyme–inhibitor complexes
to support our docking and optimization strategies.
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